NCT05285839View on ClinicalTrials.gov

Dupixent and Narrowband UVB for Atopic Dermatitis

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

December 1, 2024

Study Completion Date

December 15, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupixent

dupilumab 300mg

Trial Locations (1)

08520

RECRUITING

Eczema Treatment Center of New Jersey, East Windsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Psoriasis Treatment Center of Central New Jersey

OTHER